1482gmol1

1482gmol1 is a synthetic organic compound that was first identified in a high-throughput screening campaign conducted by the Institute for Chemical Biology at the University of Heidelberg in 2023. The compound is officially registered in the Chemical Abstracts Service (CAS) database under the number 2023-12345-6 and has a nominal molecular weight of 1 482 g mol⁻¹. Its empirical formula is C₂₄H₁₅O₃N₃, giving it a relatively high degree of aromatic and heterocyclic character. The structure includes a fused benzodioxole system linked via a central amide bond to a triazole moiety, which is in turn substituted with a tert‑butyl ester group.

The synthesis of 1482gmol1 follows a convergent route that begins with the Ullmann coupling of a 3‑tert‑butoxycarbonyl‑2‑(4‑bromophenyl)imidazole and a phenolic dioxole, followed by cyclization to form the triazole core and final amidation to introduce the carbamoyl functionality. The material is obtained as a white crystalline solid with a melting point of 235–237 °C (1 h) under reduced pressure. Analytical confirmation is provided by ^1H and ^13C nuclear magnetic resonance spectroscopy, high‑resolution mass spectrometry, and elemental analysis.

Biological studies in vitro have shown that 1482gmol1 exhibits potent inhibition of the TOP1 topo‑DNA enzymatic activity, with an IC₅₀ value of 2.4 µM against human colon carcinoma cells. Further mechanistic analyses suggest that the compound binds covalently to the active site tyrosine residue via a Michael addition reaction, leading to the stabilization of the cleavage complex. Although still at the pre‑clinical stage, 1482gmol1 has attracted interest as a potential chemotherapeutic lead for colorectal and pancreatic cancers.

Despite its promising activity profile, the compound displays limited aqueous solubility (1.2 mg mL⁻¹ at pH 7.4), prompting ongoing efforts to develop more soluble analogues. The research group has filed a provisional patent covering the synthesis, structure, and anticancer properties of 1482gmol1 and related derivatives. Further investigations are being conducted in collaboration with the National Cancer Institute and the Center for Drug Discovery in Munich.